Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid

• Published in: Alzheimer's & dementia Vol. 15; no. 8; pp. 1071 - 1080
• Main Authors: Jia, Longfei, Qiu, Qiongqiong, Zhang, Heng, Chu, Lan, Du, Yifeng, Zhang, Jiewen, Zhou, Chunkui, Liang, Furu, Shi, Shengliang, Wang, Shan, Qin, Wei, Wang, Qi, Li, Fangyu, Wang, Qigeng, Li, Yan, Shen, Luxi, Wei, Yiping, Jia, Jianping
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2019
• Subjects: Alzheimer's disease; Biomarker; Exosome; Mild cognitive impairment; tau; Aβ; tau; Biomarker; Mild cognitive impairment; Exosome; Alzheimer's disease
• ISSN: 1552-5260; 1552-5279; 1552-5279
• DOI: 10.1016/j.jalz.2019.05.002

Neuronal-derived exosomal Aβ42, T-tau, and P-T181-tau have been demonstrated to be biomarkers of Alzheimer's disease (AD). However, no study has assessed the association of Aβ42, T-tau, and P-T181-tau between exosomes and CSF. This was a multicenter study with two-stage design. The subjects included 28 AD patients, 25 aMCI patients, and 29 controls in the discovery stage; the results of which were confirmed in the validation stage (73 AD, 71 aMCI, and 72 controls). The exosomal concentrations of Aβ42, T-tau, and P-T181-tau in AD group were higher than those in aMCI and control groups (all P < .001). The level of each exosomal biomarker was highly correlated with that in CSF. This study verified the agreement between CSF and blood exosomal biomarkers and confirmed that exosomal Aβ42, T-tau, and P-T181-tau have the same capacity as those in CSF for the diagnosis of AD and aMCI.